Autopsy report · NCT04807972

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

“Strategic considerations”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 years 10 months before it stopped.
• 40 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

AbbVie

Sponsor type

Industry

Conditions

Pancreatic Cancer

Interventions

ABBV-927; Budiglimab; modified FOLFIRINOX

Participants

40

Sites

15

Countries

Australia, Israel, Puerto Rico, South Korea, Spain, United States

Trials that died the same way

• CT 327 in the "Atopy Patch Test" Model
  “Strategic decision” (82% match in meaning)
• Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
  “Strategic Reasons” (77% match in meaning)
• Rapid Amniotic Fluid (AF) Test and a Non-Invasive Vaginal Fluid (VF) Test
  “Business Strategic Decision” (76% match in meaning)
• Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
  “Strategic business decision” (76% match in meaning)
• S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
  “Strategic development reasons” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.